In the landscape of modern drug discovery, the traditional animal study has long been viewed as a linear process: dosing, observation, sacrifice, and final report. Once the pathologist signed off on the findings, the glass slides used for microscopic analysis were relegated to long-term storage—a one-way street ending in a dark archive. Today, that paradigm is undergoing a radical transformation. Driven by the maturation of digital pathology and a rigorous regulatory shift toward "New Approach Methodologies" (NAMs), the industry is turning its attention to the vast, untapped data trapped within millions of archived tissue samples.
By leveraging artificial intelligence (AI) and high-resolution digital imaging, researchers are now mining these "legacy" slides to extract molecular insights, train diagnostic models, and—most significantly—reduce the reliance on future animal testing.
The Paradigm Shift: From Physical Slides to Digital Data
The catalyst for this shift was the COVID-19 pandemic. Forced into remote workflows, pathologists were compelled to adopt digital slide scanning as a matter of survival. What began as a logistical necessity quickly revealed a deeper potential. As Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories, aptly puts it: "Before, the pathology endpoint was just a report. Now you have the digitized slide, which is pixels."
These pixels represent a goldmine of biological information. By pairing high-resolution images with existing pathology reports and molecular data, researchers are training machine learning models to identify patterns that the human eye might miss—patterns linked to specific molecular changes, disease progression, or toxicological responses. A slide that was once "read" once is now a perpetual source of data, capable of answering scientific questions that hadn’t even been formulated at the time the tissue was originally collected.
Chronology of a Regulatory Evolution
The movement toward reducing animal research is not merely a scientific aspiration; it is a policy-driven mandate. The timeline of this transition has accelerated significantly over the last several years:
- 2022: The FDA Modernization Act 2.0. This landmark legislation marked the first time the U.S. government formally allowed for non-animal methods to support applications for human clinical trials, signaling the end of the mandatory animal-testing requirement for all drug development.
- April 2024: The Rise of Alternative Methods. Charles River Laboratories launched its "Alternative Methods Advancement Project," underscoring the industry’s commitment to integrating advanced digital tools into the heart of preclinical safety testing.
- April 2025: The Roadmap for Reduction. The FDA released a formal roadmap for reducing animal testing in preclinical safety studies. The strategy is phased, beginning with monoclonal antibodies and expanding to broader biologics and chemical entities.
- September 2026: Continued Regulatory Guidance. The FDA issued updated regulations further refining the requirements for utilizing NAMs, establishing a clear trajectory where animal studies will eventually transition from the standard "default" to the exception.
Virtual Control Groups and the Arithmetic of Compassion
One of the most immediate applications of this digital shift is the development of "virtual control groups." In traditional toxicology, a significant portion of every study involves control animals—subjects that receive no drug but are otherwise handled identically to the treatment groups. This is a massive drain on resources and animal lives.
By creating robust databases of historical control data, researchers at organizations like Charles River are beginning to replace physical control groups with digital baselines. The challenge, however, is scientific rigor. "Control animals are always a big fraction of every study," Dr. Zuraw notes. "Replacing some of them with matched historical data cuts animal numbers by simple arithmetic."
To succeed, researchers must ensure that historical data is perfectly aligned with current study conditions to avoid "study drift," where environmental or biological variations are mistakenly interpreted as drug effects. The goal is to build an exhaustive, matched-data library that allows virtual controls to be used with the same confidence as a concurrent control group.
Maximizing Archived Tissue: The FFPE Revolution
Formalin-fixed, paraffin-embedded (FFPE) blocks have been the standard for tissue preservation for decades. While these blocks were historically used for manual assessment, they are now being unlocked as molecular archives.
When a drug discovery project hits an unexpected roadblock, the traditional response was to design a new animal experiment to investigate the cause. Today, researchers can return to the archived FFPE blocks from completed studies. Provided the tissue was properly stored, it can often yield molecular information regarding gene expression and protein activity, allowing scientists to correlate treatment outcomes with biological mechanisms without the need for additional animal models.
The Organisation for Economic Co-operation and Development (OECD) reinforced this in their 2025 guidance on omics analysis, providing a framework for how preserved tissue can be repurposed for modern molecular investigation. As Dr. Zuraw emphasizes, "Now you have the option to use FFPE material that was already part of a lot of studies for additional information. You don’t lose the context of the study."
The Emerging Frontier: Virtual Staining
Beyond mining historical archives, the industry is pushing into the realm of "virtual staining." This technology allows scanners to capture unstained tissue sections and use software to generate the appearance of a stain, effectively bypassing the need for traditional, chemistry-heavy laboratory staining processes.
This is more than a cost-saving measure; it is a significant technological leap. By "skipping the staining and skipping glass slides altogether," laboratories are moving toward a fully digital workflow. While much of this technology still relies on the initial capture of physical tissue, the ultimate vision is a fully digital, software-defined pathology environment. This trend is gaining momentum, with a surge in scientific literature documenting its efficacy across diverse tissue types, tracing back to the first successful demonstrations in 2019.
Implications for the Future of Drug Discovery
The implications of this shift are profound, impacting everything from the speed of drug approval to the ethical footprint of the pharmaceutical industry.
1. Accelerating Preclinical Timelines
By using digital models to predict outcomes, companies can "fail fast" or identify toxicity issues much earlier in the pipeline. This reduces the number of dead-end projects that reach expensive clinical trial stages.
2. Regulatory Compliance as a Competitive Edge
As the FDA moves to make NAMs the standard, companies that have already invested in digital pathology and historical data mining will have a distinct advantage. They will be the "early adopters" who have already mapped the regulatory landscape, effectively setting the standard for others to follow.
3. Ethical and ESG Goals
For pharmaceutical companies, the move away from animal testing is a critical component of Environmental, Social, and Governance (ESG) criteria. Beyond the ethical imperative of reducing animal welfare impacts, the move is economically sustainable, reducing the high costs associated with maintaining large animal colonies.
Conclusion: A Snowball Effect
The transition to a digital-first pathology ecosystem is currently in its "precedent-setting" phase. As Dr. Zuraw notes, the industry requires early adopters to troubleshoot these new methods, demonstrate their reliability to regulators, and prove that digital insights are as robust—if not more so—than traditional, manual assessments.
"I hope it becomes a snowball effect," says Zuraw. By proving that the data sources are not just archives, but active, living assets, the research community is fundamentally changing what it means to conduct a preclinical study. We are moving toward a future where the most valuable tool in the laboratory isn’t the microscope, but the intelligence applied to the digital images those microscopes once produced. The era of the one-way street is over; in its place is a circular, data-driven cycle that honors the animals used in past studies by extracting every possible drop of knowledge from the work they helped initiate.
About the Author
